期刊
BIOLOGICAL CHEMISTRY
卷 404, 期 4, 页码 279-289出版社
WALTER DE GRUYTER GMBH
DOI: 10.1515/hsz-2022-0222
关键词
fluorine-18-labeled PET tracer; labeling of CNS regions in vivo; molecular interactions of 3-benzazepines with GluN2B-NMDA receptors; NMDA receptors with GluN2B subunit; pharmacokinetic properties; tetrahydro-3-benzazepinediols
GluN2B-NMDA receptors play a key role in neurological and neurodegenerative disorders. A new GluN2B-NMDA receptor modulator was developed with promising affinity and pharmacological activity, which could be suitable for human application.
GluN2B-NMDA receptors play a key role in several neurological and neurodegenerative disorders. In order to develop novel negative allosteric GluN2B-NMDA receptor modulators, the concept of conformational restriction was pursued, i.e. the flexible aminoethanol substructure of ifenprodil was embedded into a more rigid tetrahydro-3-benzazepine system. The resulting tetrahydro-3-benzazepine-1,7-diol (+/-)-2 (WMS-1410) showed promising receptor affinity in receptor binding studies (K (i) = 84 nM) as well as pharmacological activity in two-electrode-voltage-clamp experiments (IC (50) = 116 nM) and in cytoprotective assays (IC (50) = 18.5 nM). The interactions of (R)-2 with the ifenprodil binding site of GluN2B-NMDA receptors were analyzed on the molecular level and the foot-in-the-door mechanism was developed. Due to promising pharmacokinetic parameters (logD(7.4) = 1.68, plasma protein binding of 76-77%, sufficient metabolic stability) F-substituted analogs were prepared and evaluated as tracers for positron emission tomography (PET). Both fluorine-18-labeled PET tracers [F-18]11 and [F-18]15 showed high brain uptake, specific accumulation in regions known for high GluN2B-NMDA receptor expression, but no interactions with sigma (1) receptors. Radiometabolites were not observed in the brain. Both PET tracers might be suitable for application in humans.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据